Johnson & Johnson (NYSE:JNJ) stock fell 0.35% (As on April 15, 11:21:51 AM UTC-4, Source: Google Finance) after the company revised its full-year forecast, cutting the earnings outlook while raising the sales guidance range. However, the company said that tariffs on pharmaceuticals can create supply chain disruptions and that favorable tax policies would be a more effective tool to boost U.S. manufacturing capacity of both drugs and medical devices.

Moreover, Innovative Medicine worldwide operational sales grew 4.2% driven primarily by DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, SPRAVATO in Neuroscience, and XARELTO in Cardiovascular/Metabolism/Other. Growth was partially offset by an approximate (810) basis points impact from STELARA in Immunology. MedTech worldwide operational sales grew 4.1%, with net acquisitions and divestitures positively impacting growth by 2.8%. Growth was driven primarily by Abiomed in Cardiovascular and wound closure products in General Surgery. Growth was partially offset by Spine, Sports & Other in Orthopaedics. Cancer drug Darzalex generated $3.24 billion in revenue, up 20% from the prior year and ahead of the $3.1 billion forecast. Johnson & Johnson’s psoriasis drug Stelara brought in $1.63 billion, down 34% year-over-year, but still narrowly above the $1.61 billion estimate.

JNJ in the first quarter of FY25 has reported the adjusted earnings per share of $2.77, beating the analysts’ estimates for the adjusted earnings per share of $2.58. The company had reported the adjusted revenue growth of 2.4 percent to $21.9 billion in the first quarter of FY25, beating the analysts’ estimates for revenue of $21.57 billion.

For the full year 2025, Johnson & Johnson now expects earnings per share between $10.50 and $10.70, compared to its previous range of $10.75 to $10.95 and the consensus estimate of $10.50.

The drugmaker raised its full-year sales outlook to between $91 billion and $91.8 billion, up from a prior range of $89.2 billion to $90 billion. The New Jersey-based healthcare conglomerate raised its 2025 sales forecast by $700 million to reflect the addition of schizophrenia drug Caplyta to its portfolio, which it expects to be approved this year. The company also said it expects Spravato, a nasal spray used to treat depression, to bring in $3 billion to $3.5 billion in annual sales by 2028. Even with the expected boost from Caplyta, J&J maintained its profit estimate to reflect the impact of tariffs and dilution from its $14.6 billion deal to buy neurological drugmaker Intra-Cellular.